Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08SCF
|
||||
| Former ID |
DNC014317
|
||||
| Drug Name |
Philanthotoxin-343
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H41N5O3
|
||||
| Canonical SMILES |
CCCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NCCCNCCCCNCCCN
|
||||
| InChI |
1S/C23H41N5O3/c1-2-7-22(30)28-21(18-19-8-10-20(29)11-9-19)23(31)27-17-6-16-26-14-4-3-13-25-15-5-12-24/h8-11,21,25-26,29H,2-7,12-18,24H2,1H3,(H,27,31)(H,28,30)/t21-/m0/s1
|
||||
| InChIKey |
DTWANULJDRVTFI-NRFANRHFSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor 1 | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Long-term depression | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Pathway Interaction Database | EPHB forward signaling | ||||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Trafficking of AMPA receptors | |||||
| Trafficking of GluR2-containing AMPA receptors | |||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| Cargo concentration in the ER | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| BDNF signaling pathway | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2010 Feb 15;18(4):1381-7. Epub 2010 Jan 6.Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.